Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation of sodium zirconium cyclosilicate after hospital discharge in chronic kidney disease patients treated for hyperkalaemia
NL-OMON51555Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hyperkalemia comparing Discharge with sodium zirconium cyclosilicate with Discharge with standard of care (2 arms). Primary endpoint: Normokalaemia at 180 days post-discharge. Started Aug 2022; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NL-OMON51555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51555.